SAN ANTONIO — Promising data don't always equal a stock pop. Viking ... biotech's Phase 3 readiness, mid-stage oral plans and an amylin drug ...
News
- Viking CEO on 'shocking' market reaction to oral obesity data, preparing for Phase 3
- Ultragenyx: Q3 Earnings Snapshot - San Antonio Express-News
The biotechnology company posted revenue of $139.5 ... A cold front will approach the San Antonio area through Monday and it could bring with.
- Abstract Describing Significant Results of Crofelemer for Cancer - GuruFocus
... Biotechnology NAS:JAGX. Abstract Describing Significant Results of ... San Antonio Breast Cancer Symposium (SABCS). Patients with breast ...
- Zealand's Weight-Loss Drug Has Minimal Side Effects in Study - Bloomberg
... biotech said Tuesday at the ObesityWeek conference in San Antonio. The group lost an average of 8.6% of their body weight over 16 weeks. Patients ...
- BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast ...
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13. November 5, 2024 |. 4 ...